annb0t
Top 20
Immutep Limited (NASDAQ: IMMP) has announced new interim data from the Phase 2 TACTI002 trial of eftilagimod alpha (efti or IMP321), combined with Merck & Co Inc's Keytruda (pembrolizumab).
The trial included 36 patients with PD-L1 unselected 2nd line PD-X refractory metastatic non-small cell lung cancer (NSCLC). The patients had advanced disease that progressed after prior standard of care treatment with either anti-PD-(L)1 monotherapy or chemotherapy / anti-PD-(L)1 combo therapy. As of the da...
>>> Read more: Why Are Immutep Shares Trading Higher?
The trial included 36 patients with PD-L1 unselected 2nd line PD-X refractory metastatic non-small cell lung cancer (NSCLC). The patients had advanced disease that progressed after prior standard of care treatment with either anti-PD-(L)1 monotherapy or chemotherapy / anti-PD-(L)1 combo therapy. As of the da...
>>> Read more: Why Are Immutep Shares Trading Higher?
